Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus.
Platzbecker
U
U
Mohr
B
B
von Bonin
M
M
Binder
M
M
Schetelig
J
J
Ehninger
G
G
Bornhäuser
M
M
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D049109:Cell Proliferation; D002895:Chromosomes, Human, Pair 5; D003582:Cytogenetics; D051766:Early Growth Response Protein 1 / Q000235:genetics*; D017353:Gene Deletion; D006801:Humans; D000077269:Lenalidomide; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000628:therapy*; D008297:Male; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous / Q000379:methods*
D000970:Antineoplastic Agents; C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; D013792:Thalidomide; D000077269:Lenalidomide